

Ref. No: 2593
Date: 02/06/26
Subject: Biologics Medicines in Gastroenterology

REQUEST

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Etrasimod
- Filgotinib
- Golimumab - Simponi
- Golimumab Biosimilar
- Infliximab - Remicade
- Infliximab Biosimilar
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab - Stelara
- Ustekinumab Biosimilar
- Vedolizumab
- Guselkumab

Q2. Could you please provide the numbers of patients treated for Crohn's Disease in the last 3 months with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilars
- Golimumab - Simponi
- Golimumab Biosimilar
- Infliximab - Remicade
- Infliximab Biosimilars
- Risankizumab

- Upadacitinib
- Ustekinumab - Stelara
- Ustekinumab Biosimilar
- Vedolizumab
- Mirikizumab
- Guselkumab

RESPONSE

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira - <5
- Adalimumab Biosimilar - 131
- Etrasimod - 0
- Filgotinib - 12
- Golimumab – Simponi - 0
- Golimumab Biosimilar - 0
- Infliximab – Remicade - <5
- Infliximab Biosimilar - 299
- Mirikizumab - 18
- Ozanimod - <5
- Risankizumab - 29
- Tofacitinib - 11
- Upadacitinib - 36
- Ustekinumab – Stelara - 13
- Ustekinumab Biosimilar - 175
- Vedolizumab - 76
- Guselkumab - <5

Q2 – Unable to answer as pharmacy do not hold information about specific indications.